4 completed, 3 terminated, 1 recruiting. 6 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Terminated 3, Completed 2, Recruiting 1 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Aptose Biosciences Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS CG-806 - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Terminated | Aptose Biosciences Inc. | 45 | 2020-10-06 | 2025-03-07 |
| A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas CG-806 - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Terminated | Aptose Biosciences Inc. | 36 | 2019-04-30 | 2025-03-07 |
| Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion - Leukemia, Myeloid, Acute, Refractory AML | Phase 1 / Phase 2 | Recruiting | Aptose Biosciences Inc. | 240 | 2019-03-11 | 2025-08-26 |
| A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS APTO-253 - Acute Myelogenous Leukemia in Relapse, Acute Myelogenous Leukemia, Relapsed, Adult | Phase 1 | Terminated | Aptose Biosciences Inc. | 21 | 2014-10-01 | 2022-08-22 |
| A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours LOR-253 HCl - Advanced or Metastatic Solid Tumours | Phase 1 | Completed | Aptose Biosciences Inc. | 36 | 2011-01-01 | 2014-02-25 |
| Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) GTI-2040 - Acute Myeloid Leukemia | Phase 2 | Completed | Aptose Biosciences Inc. | 27 | 2007-08-01 | 2015-07-27 |
| A Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic Cancer Virulizin® - Pancreatic Cancer | Phase 3 | Completed | Aptose Biosciences Inc. | 400 | 2002-07-01 | 2008-01-07 |
| Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma GTI-2040 - Carcinoma, Renal Cell, Metastases, Neoplasm | Phase 1 / Phase 2 | Completed | Aptose Biosciences Inc. | 43 | 2002-03-01 | 2008-01-07 |
Leukemia, Myeloid, Acute (4) · Recurrence (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Carcinoma, Renal Cell (1) · Leukemia (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1)
GTI2040 (2) · APTO-253 (1) · Azacitidine (1) · Infusions, Intravenous (1) · venetoclax (1) · virulizin (1)
United States (7) · Australia (1) · Germany (1) · New Zealand (1) · South Korea (1) · Spain (1)
Rafael Bejar, MD, PhD (2) · Andrea Cercek, M.D. (1) · Jennifer Wheler, MD (1) · Naval Daver, MD (1) · Rafael Bejar, MD., PhD. (1) · Rebecca B Klisovic, MD (1)
PMID 36865133, PMID 38871487, PMID 39665627
2023 (1)